PWA
NBIX icon

Physician Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Physician Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.4K Buy
489
+2
+0.4% +$297 0.01% 344
2026
Q1 		$64.2K Hold
487
– – 0.01% 353
2025
Q4 		$69.1K Buy
487
+4
+0.8% +$579 0.01% 329
2025
Q3 		$67.8K Hold
483
– – 0.01% 324
2025
Q2 		$60.7K Hold
483
– – 0.01% 318
2025
Q1 		$53.4K Hold
483
– – 0.01% 325
2024
Q4 		$65.9K Buy
+483
New +$59.7K 0.01% 307

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Physician Wealth Advisors's NBIX Position: Q2 2026 in Review

Physician Wealth Advisors increased its Neurocrine Biosciences (NBIX) stake by 0.41% in Q2 2026, buying an estimated $297 and bringing the position to 489 shares worth $82.4K. The position accounts for 0.01% of the portfolio, ranked #344.

Physician Wealth Advisors first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Physician Wealth Advisors held 489 shares of Neurocrine Biosciences worth $82.4K as of Q2 2026.
  • Physician Wealth Advisors bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up 0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #344 holding.
  • Physician Wealth Advisors first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.